EVH Stock Up 43% after 11-Day Win Streak
Evolent Health (EVH) stock hit day 11 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 43% return. The company has gained about $564 Mil in value over the last 11 days, with its current market capitalization at about $1.3 Bil. The stock remains 4.3% above its value at the end of 2024. This compares with year-to-date returns of 5.9% for the S&P 500.
Comparing EVH Stock Returns With The S&P 500
The following table summarizes the return for EVH stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | EVH | S&P 500 |
|---|---|---|
| 1D | 0.9% | 0.5% |
| 11D (Current Streak) | 43.4% | 3.2% |
| 1M (21D) | 55.0% | 4.9% |
| 3M (63D) | 21.2% | 10.6% |
| YTD 2025 | 4.3% | 5.9% |
| 2024 | -65.9% | 23.3% |
| 2023 | 17.6% | 24.2% |
| 2022 | 1.5% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 134 S&P constituents with 3 days or more of consecutive gains and 8 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 41 | 7 |
| 4D | 26 | 0 |
| 5D | 42 | 0 |
| 6D | 1 | 1 |
| 7D or more | 24 | 0 |
| Total >=3 D | 134 | 8 |
Key Financials for Evolent Health (EVH)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $2.0 Bil | $2.6 Bil |
| Operating Income | $-21.1 Mil | $-14.1 Mil |
| Net Income | $-113.0 Mil | $-61.6 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $646.5 Mil | $483.6 Mil |
| Operating Income | $-1.3 Mil | $4,000 |
| Net Income | $-22.8 Mil | $-64.6 Mil |
While EVH stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.